Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock — Update
By Colin Kellaher
Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.
Boston Scientific on Thursday said the deal values Penumbra at $374 a share, a 19% premium to Wednesday's closing price of $313,43 for the Alameda, Calif., company.
The deal, which carries an enterprise value of around $14.5 billion minus Penumbra's roughly $470 million net cash and short-term investments, is slated to close later this year.
Boston Scientific said Penumbra stockholders can elect to receive $374 in cash or 3.8721 Boston Scientific shares for each share held, subject to proration so that the total consideration is about 73% cash and 27% stock.
Penumbra shares were recently up 14% to $358 in premarket trading, while shares of Boston Scientific slipped 2.9% to $91.
The Marlborough, Mass., medical-technology company said it plans to finance the roughly $11 billion cash portion of the deal with cash on hand and new debt.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 15, 2026 07:35 ET (12:35 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States